Effects of the dual peroxisome proliferatoractivated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: A Phase IIb, randomized study

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Ruilope, Luis ^a   Hanefeld, Markolf ^b   Lincoff, A Michael ^c   Viberti, Giancarlo ^d   Meyer Reigner, Sylvie ^e   Mudie, Nadejda ^e   Kirk, Dominika Wieczorek ^e   Malmberg, Klas ^e,f   Herz, Matthias ^e  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Leveland Clinic   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Aleglitazar; AleNephro; EGFR; Pioglitazone; PPAR ; Serum creatinine; Type 2 diabete

Indexed keywords

ALEGLITAZAR; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; OXAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIOPHENE DERIVATIVE;

AGED; ARTICLE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; FRACTURE; HEART DEATH; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER DISEASE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; MUSCLE DISEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; AGONISTS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; DYSLIPIDEMIAS; GLOMERULUS FILTRATION RATE; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; THERAPEUTIC EQUIVALENCE;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; OXAZOLES; PPAR ALPHA; PPAR GAMMA; RENAL INSUFFICIENCY, CHRONIC; THERAPEUTIC EQUIVALENCY; THIAZOLIDINEDIONES; THIOPHENES;

EID: 84928430938     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-180     Document Type: Article

References (33)

1. Centers of Disease Control and Prevention: National Diabetes Statistics Report. 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/nationaldiabetes-report-web.pdf.
2. Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, Després JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, et al: Identification and management of cardiometabolic risk in Canada: A position paper by the cardiometabolic risk working group (executive summary). Can J Cardiol 2011, 27:124-131.
3. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
4. Mazzone T, Chait A, Plutzky J: Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
6. Libby P: The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005, 46:1225-1228.
7. Dietz M, Mohr P, Kuhn B, Maerki HP, Hartman P, Ruf A, Benz J, Grether U, Wright MB: Comparative molecular profiling of the PPARalpha/gamma activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. Chem Med Chem 2012, 7:1101-1111.
8. Hansen BC, Tigno XT, Benardeau A, Meyer M, Sebokova E, Mizrahi J: Effects of aleglitazar, a balanced dual peroxisome proliferator-Activated receptor alpha/gamma agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. Cardiovasc Diabetol 2011, 10:7-14.
9. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M: Effect of the dual peroxisome proliferator-Activated receptor-Alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135.
10. Herz M, Gaspari F, Perico N, Viberti G, Urbanowska T, Rabbia M, Kirk DW: Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol 2011, 151:136-142.
11. Apperloo AJ, De Zeeuw D, De Jong PE: A short-Term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-Term stability of renal function. Kidney Int 1997, 51:793-797.
12. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Ryden L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE, AleCardio Investigators: Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus: The AleCardio Randomized Clinical Trial. JAMA 2014, 311:1515-1525.
13. Rigalleau V, Lasseur C, Perlemoine C, Barthe N, Raffaitin C, Liu C, Chauveau P, Baillet-Blanco L, Beauvieux MC, Combe C, Gin H: Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation? Diabetes Care 2005, 28:838-843.
14. Schneider CA, Ferrannini E, DeFronzo R, Schernthaner G, Yates J, Erdmann E: Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008, 19:182-187.
15. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, Warram JH: Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005, 16:1404-1412.
16. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D: Glycemic status and development of kidney disease: The Framingham Heart Study. Diabetes Care 2005, 28:2436-2440.
17. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators: Effects of long-Term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
18. The ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
19. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC, Fenofibrate Intervention and Event Lowering in Diabetes Study investigators: Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011, 54:280-290.
20. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT: Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010, 5:1003-1009.
21. Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K, FIELD Study Investigators: Benefits and safety of long-Term fenofibrate therapy in people with type 2 diabetes and renal impairment: The FIELD study. Diabetes Care 2012, 35:218-225.
22. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J: Reno-protective effects of renin-Angiotensin system blockade in type 2 diabetic patients: A systematic review and network meta-Analysis. Diabetologia 2012, 55:566-578.
23. Newaz MA, Ranganna K, Oyekan AO: Relationship between PPARalpha activation and NO on proximal tubular Na + transport in the rat. BMC Pharmacol 2004, 4:1.
24. Zhou Y, Luo P, Chang HH, Huang H, Yang T, Dong Z, Wang CY, Wang MH: Clofibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension. Kidney Int 2008, 74:1040-1048.
25. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000, 57:1803-1817.
26. Dobre D, Lambers Heerspink HJ, De Zeeuw D: Reducing cardiovascular risk: protecting the kidney. Eur Heart J Suppl 2009, 11:F39-F46.
27. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
28. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl JMed 2001, 345:851-860.
29. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN: Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A metaanalysis. Am J Kidney Dis 2010, 55:835-847.
30. Jin HM, Pan Y: Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Kidney Blood Press Res 2007, 30:203-211.
31. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam A, Kirchner K, Lorber D, Marcovina S, Sivitz W, Sperl-Hillen J, Bonds DE, Ginsberg HN: Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012, 35:1008-1014.
32. Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR: Effects of long-Term fenofibrate treatment on markers of renal function in type 2 diabetes: The FIELD Helsinki substudy. Diabetes Care 2010, 33:215-220.
33. Xu Y, Schnorrer P, Proietto A, Kowalski G, Febbraio MA, Acha-Orbea H, Dickins RA, Villadangos JA: IL-10 controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression. J Immunol 2011, 186:3666-3673.